Cash Flow Statement (Annual)

GHDX / Genomic Health, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Profit Loss - - - - - - -33,308 -13,919 -3,857
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletion And Amortization 6,591 7,180 7,310 5,471 6,324 6,870 7,069 8,933 11,759
    Share Based Compensation 10,155 10,344 11,735 15,104 17,457 16,538 16,005 18,303 20,256
    Capitalized Computer Software Impairments1 - - - - - - 635 2,600 76
    Impairment Of Long Lived Assets To Be Disposed Of - - - - - - 123 56 22
    Gain Loss On Sale Of Property Plant Equipment 44 45 7 86 - 51 80 -33 -35
    Issuance Of Stock And Warrants For Services Or Claims - - 130 172 230 230 200 200 200
    Equity Securities Fv Ni Realized Gain - - - - - - - - -
    Equity Securities Fv Ni Unrealized Gain - - - - - - - - -
    Extinguishment Of Debt Amount - - - - - - - - -
    Deferred Income Tax Expense Benefit - - - - - - -1,548 727 820
  Increase Decrease In Operating Capital
    Increase Decrease In Accounts Receivable 2,316 3,183 6,771 1,176 7,193 5,470 2,248 -1,985 -4,018
    Increase Decrease In Prepaid Deferred Expense And Other Assets 1,127 2,365 633 1,599 1,448 -741 1,292 4,550 -55
    Increase Decrease In Accounts Payable -594 2,664 3,057 -2,144 1,238 985 949 -4,579 -2,308
    Increase Decrease In Employee Related Liabilities 2,031 1,164 2,222 1,636 1,566 3,824 4,531 5,661 -2,947
    Increase Decrease In Accrued Liabilities And Other Operating Liabilities 1,021 938 -1,250 1,923 1,617 3,088 -2,963 1,645 4,164
  Net Cash Provided By Used In Operating Activities - - - - - - -11,831 13,456 30,593
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment 3,744 4,442 6,183 9,850 10,992 10,455 23,483 19,786 13,276
  Proceeds From Sale Of Property Plant And Equipment - - - 206 16 122 70 8 10
  Payments To Acquire Marketable Securities - - - - - - - - -
  Proceeds From Maturity Of Marketable Securities - - - - - - - - -
  Proceeds From Sale Of Marketable Securities - - - - - - - - -
  Payments To Acquire Other Investments - 500 2,300 4,963 5,000 2,000 - 6,100 2,000
  Net Cash Provided By Used In Investing Activities - - - - - - 6,283 -19,126 -42,558
Net Cash Provided By Used In Financing Activities
  Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 1,736 2,983 9,688 17,492 13,743 12,030 12,197 17,010 21,776
  Payments Related To Tax Withholding For Share Based Compensation - - - 1,272 2,845 3,647 3,842 3,469 4,697
  Net Cash Provided By Used In Financing Activities - - - - - - 8,355 13,541 17,079
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect - - - - - - - - -
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - - -
Noncash Investing And Financing Items
  Capital Expenditures Incurred But Not Yet Paid - - 1,010 1,168 1,138 1,809 3,847 1,452 717
  Assets Fair Value Adjustment - - - - - - 4,269 -316 -495

Peers - Medical Laboratories (8071)

Related News Stories

Here's Why You Should Invest in GNC Holdings (GNC) Right Now

2018-10-16 zacks
GNC Holdings, Inc. (GNC - Free Report) has been gaining investor confidence on stellar results over an extended period. Year to date, the company’s stock has outperformed its industry. The stock has gained 11.2% against the industry’s 2.2% rise. (0-2)

Amedisys to Buy Compassionate Care Hospice, Share Price Down

2018-10-15 zacks
Amedisys, Inc. (AMED - Free Report) recently inked an agreement to buy national hospice care provider —Compassionate Care Hospice. Amedisys is slated to pay $340 million, which includes $50 million in payments related to a tax asset and working capital for acquiring 100% ownership interest in Compassionate Care Hospice. The transaction is expected to close by Feb 1, 2019. (1-0)

Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus

2018-10-11 zacks
Myriad Genetics recently signed a commercialization plan with Pfizer Inc. (PFE - Free Report) for FDA approval to use its BRACAnalysis CDx as a companion diagnostic with the latter’s talazoparib. Meanwhile, Thermo Fisher Scientific Inc. (TMO - Free Report) announced the sixth licensing agreement for its B·R·A·H·M·S PCT (procalcitonin) biomarker. In fact, there are many similar developments that clearly point toward the rapid emergence of molecular diagnostics in the MedTech space. (4-0)

Here's Why You Should Invest in Genomic Health (GHDX) Now

2018-10-09 zacks
Genomic Health, Inc. (GHDX - Free Report) has been gaining investor confidence on stellar results over an extended period. Over the past year, the company’s share price has outperformed its industry. The stock has gained 103.2% against the industry’s 18.6% fall. Also, the company has fared better than the S&P 500’s 13.9% rise. (1-0)

Genomic Health's New Data on Oncotype DX GPS to Boost Uptake

2018-10-04 zacks
Genomic Health, Inc. (GHDX - Free Report) recently announced the publication of real-world clinical data supporting the use of the Oncotype DX Genomic Prostate Score (GPS) test, which has resulted in substantially greater use of active surveillance compared to no testing. Results of this new study were published in Reviews in Urology. (3-1)

CUSIP: 37244C101